ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
JPY 2041.0
(-0.34%)
JPY 2041.0
(-0.34%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 7.54 Billion JPY | 78.03% |
| 2022 | 4.23 Billion JPY | -1.21% |
| 2021 | 4.29 Billion JPY | 58.13% |
| 2020 | 2.71 Billion JPY | 318.03% |
| 2019 | 649 Million JPY | -62.79% |
| 2018 | 1.74 Billion JPY | -26.97% |
| 2017 | 2.38 Billion JPY | -18.89% |
| 2016 | 2.94 Billion JPY | 319.97% |
| 2015 | 701 Million JPY | -41.24% |
| 2014 | 1.19 Billion JPY | 141.01% |
| 2013 | 495 Million JPY | -55.57% |
| 2012 | 1.11 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.28 Billion JPY | 1.1% |
| 2024 Q1 | 1.27 Billion JPY | 17.11% |
| 2023 FY | 7.54 Billion JPY | 78.03% |
| 2023 Q1 | 1.42 Billion JPY | 2496.36% |
| 2023 Q2 | 2.7 Billion JPY | 89.15% |
| 2023 Q3 | 2.32 Billion JPY | -13.77% |
| 2023 Q4 | 1.08 Billion JPY | -53.33% |
| 2022 Q4 | 55 Million JPY | -97.01% |
| 2022 FY | 4.23 Billion JPY | -1.21% |
| 2022 Q3 | 1.83 Billion JPY | 79.57% |
| 2022 Q2 | 1.02 Billion JPY | -22.68% |
| 2022 Q1 | 1.32 Billion JPY | 536.06% |
| 2021 Q3 | 6.87 Billion JPY | 276.63% |
| 2021 FY | 4.29 Billion JPY | 58.13% |
| 2021 Q4 | 208 Million JPY | -96.98% |
| 2021 Q2 | -3.89 Billion JPY | -454.64% |
| 2021 Q1 | 1.09 Billion JPY | 319.08% |
| 2020 Q3 | 899 Million JPY | 10.58% |
| 2020 FY | 2.71 Billion JPY | 318.03% |
| 2020 Q1 | 739 Million JPY | 278.07% |
| 2020 Q2 | 813 Million JPY | 10.01% |
| 2020 Q4 | 262 Million JPY | -70.86% |
| 2019 Q2 | 14 Million JPY | -97.51% |
| 2019 Q3 | 487 Million JPY | 3378.57% |
| 2019 Q4 | -415 Million JPY | -185.22% |
| 2019 Q1 | 563 Million JPY | 219.28% |
| 2019 FY | 649 Million JPY | -62.79% |
| 2018 FY | 1.74 Billion JPY | -26.97% |
| 2018 Q4 | -472 Million JPY | -132.04% |
| 2018 Q3 | 1.47 Billion JPY | 561.76% |
| 2018 Q2 | -319 Million JPY | -130.04% |
| 2018 Q1 | 1.06 Billion JPY | 266.46% |
| 2017 FY | 2.38 Billion JPY | -18.89% |
| 2017 Q2 | 600 Million JPY | -42.47% |
| 2017 Q3 | 1.38 Billion JPY | 130.5% |
| 2017 Q4 | -638 Million JPY | -146.13% |
| 2017 Q1 | 1.04 Billion JPY | 207.97% |
| 2016 FY | 2.94 Billion JPY | 319.97% |
| 2016 Q1 | 526 Million JPY | 238.79% |
| 2016 Q2 | 749 Million JPY | 42.4% |
| 2016 Q3 | 2.63 Billion JPY | 251.8% |
| 2016 Q4 | -966 Million JPY | -136.66% |
| 2015 Q4 | -379 Million JPY | -155.33% |
| 2015 Q3 | 685 Million JPY | 229.33% |
| 2015 Q2 | 208 Million JPY | 11.23% |
| 2015 Q1 | 187 Million JPY | 164.93% |
| 2015 FY | 701 Million JPY | -41.24% |
| 2014 Q3 | 645 Million JPY | 19.22% |
| 2014 Q1 | 295 Million JPY | 137.53% |
| 2014 FY | 1.19 Billion JPY | 141.01% |
| 2014 Q4 | -288 Million JPY | -144.65% |
| 2014 Q2 | 541 Million JPY | 83.39% |
| 2013 Q3 | 759 Million JPY | 5321.43% |
| 2013 Q1 | 508 Million JPY | 280.78% |
| 2013 Q2 | 14 Million JPY | -97.24% |
| 2013 FY | 495 Million JPY | -55.57% |
| 2013 Q4 | -786 Million JPY | -203.56% |
| 2012 FY | 1.11 Billion JPY | 0.0% |
| 2012 Q4 | -281 Million JPY | -142.9% |
| 2012 Q2 | 329 Million JPY | 0.0% |
| 2012 Q3 | 655 Million JPY | 99.09% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 3.2 Billion JPY | -135.413% |
| Takeda Pharmaceutical Company Limited | 144.06 Billion JPY | 94.763% |
| Sumitomo Pharma Co., Ltd. | -314.96 Billion JPY | 102.395% |
| Shionogi & Co., Ltd. | 162.03 Billion JPY | 95.343% |
| Wakamoto Pharmaceutical Co.,Ltd. | 108.95 Million JPY | -6824.623% |
| Nippon Shinyaku Co., Ltd. | 25.85 Billion JPY | 70.814% |
| Kaken Pharmaceutical Co., Ltd. | 8.02 Billion JPY | 5.981% |
| Eisai Co., Ltd. | 42.4 Billion JPY | 82.208% |
| Morishita Jintan Co., Ltd. | 697 Million JPY | -982.496% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.96 Billion JPY | 45.988% |
| Mochida Pharmaceutical Co., Ltd. | 4.54 Billion JPY | -65.934% |
| Fuso Pharmaceutical Industries,Ltd. | 1.37 Billion JPY | -447.93% |
| Nippon Chemiphar Co., Ltd. | -180 Million JPY | 4291.667% |
| Tsumura & Co. | 16.7 Billion JPY | 54.839% |
| Kissei Pharmaceutical Co., Ltd. | 11.16 Billion JPY | 32.392% |
| Torii Pharmaceutical Co., Ltd. | 4.11 Billion JPY | -83.176% |
| Towa Pharmaceutical Co., Ltd. | 16.17 Billion JPY | 53.348% |
| Fuji Pharma Co., Ltd. | 3.43 Billion JPY | -119.651% |
| Zeria Pharmaceutical Co., Ltd. | 7.73 Billion JPY | 2.409% |
| KYORIN Holdings, Inc. | 5.32 Billion JPY | -41.77% |
| Taiko Pharmaceutical Co.,Ltd. | -4.89 Billion JPY | 254.168% |
| Daito Pharmaceutical Co.,Ltd. | 3.29 Billion JPY | -128.983% |
| SymBio Pharmaceuticals Limited | -1.96 Billion JPY | 484.397% |
| MedRx Co., Ltd | -932 Million JPY | 909.549% |
| Mizuho Medy Co.,Ltd. | 3.77 Billion JPY | -99.908% |
| Solasia Pharma K.K. | -1.11 Billion JPY | 778.507% |
| Modalis Therapeutics Corporation | -2.39 Billion JPY | 415.45% |
| Sawai Group Holdings Co., Ltd. | 13.69 Billion JPY | 44.907% |
| Cyfuse Biomedical K.K. | -589.21 Million JPY | 1380.526% |
| Toho Holdings Co., Ltd. | 20.65 Billion JPY | 63.475% |
| Koa Shoji Holdings Co.,Ltd. | 2.94 Billion JPY | -156.081% |